Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Premium

Umang Vohra, MD & Global CEO, Cipla and Samina Hamied, Executive Vice-chairperson, Cipla | Photo: Kamlesh Pednekar

7 min read Last Updated : May 19 2022 | 6:04 AM IST

Cipla was at the forefront of the pharmaceutical industry’s response to the Covid-19 pandemic, whether by tying up with MNCs for products like remdesivir or tocilizumab, or ramping up production

Topics : Cipla Indian pharma companies Ayushman Bharat Fosun Pharmaceutical

First Published: May 19 2022 | 6:04 AM IST

Explore News

Stock Market Updates World Heart Day 2023 Asian Games 2023 Kabaddi schedule Latest News Live Asian Games LIVE updates India Cricket World Cup Squad Hookah Ban in Haryana Gold-Silver Price MCX Share Price Asian Games 2023 September 30 schedule

Companies News

Air India completes acquisition of its 1st A350 aircraft through GIFT City Jalan Kalrock Consortium infuses Rs 100 crore in cash-strapped Jet Airways

Sports News

Asian Games 2023 September 30 schedule: India event timings, streaming Asian Games Day 6 Highlights: Historic shot put medal push IND tally to 33

India News

Punjab farmers continue three-day 'rail roko' agitation over MSP demand War in Ukraine pushes India to obtain more self-propelled guns to arsenal

Economy News

Adani partnership remains steadfast: IHC on Adani units' stake sale Sugar market eyes restrictions from India after lower monsoon rains

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Continue

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Also Read

Hospital admissions under Ayushman Bharat double in the last 6 months

BS Awards for Corporate Excellence 2021: Samina Hamied lauds team effort

Sun Pharma Q3 results: Net profit rises 11% to Rs 2,058.8 crore

Reforming provider payments, price setting for Ayushman Bharat

Strong specialty sales and volumes keep it sunny for Sun Pharma

Aatmanirbhar Bharat needs Aatmanirbhar banking sector: CII's Sanjiv Bajaj

Keen to invest more in Indian software, fintech: Insight Partners top brass

We aren't giving out data continuum of the user: Amagi's Baskar Subramanian

Slowdown, earnings pressure are temporary: Dalmia Cement (Bharat) MD & CEO

India can't be scoffed at by global chipmakers: Ather Energy's Tarun Mehta

Explore News